Creative Medical surges on positive long-term data for back pain procedure
23/03/2022 14:08
** Shares of biotech Creative Medical Technology Holdings
Inc CELZ.O rise ~104% to $3.47
** Co says two-year follow-up data confirms significant
efficacy and no serious adverse effects in patients using its
StemSpine procedure for treating chronic lower back pain
urn:newsml:reuters.com:*:nPn9QQHYNa
** StemSpine is a patented procedure that utilizes a
patient's own bone marrow aspirate for the treatment of chronic
lower back pain
** StemSpine procedure resulted in an efficacy rate of 87%
in the treated patients - CELZ
** Co plans to submit manuscript for publication in
peer-reviewed journal and present data at future conferences
(Reporting by Mrinalika Roy in Bengaluru)
((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))
Recent news on Creative Medical Technology Holdings
See all newsBrief: Creative Medical Technology Buys 4 Million Biodefense Shares For $200,000 Cash And 1 Million Shares On Sept 24
Brief: Creative Medical Technology Holdings Successfully Completes Enrollment And Treatment Across Entire FDA-Cleared Adapt Trial, Including Opioid Cohort, Advancing Celz-201 / Olastrocel Toward Rmat Evaluation And Phase 3 Planning
Creative Medical Technology Holdings Inc reports results for the quarter ended June 30 - Earnings Summary
NASDAQ RESUMED AT 11:07 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:02 AM